Ozempic and Simvastatin Interaction: What Patients and Clinicians Need to Know

Does Ozempic interact with simvastatin?

Ozempic is approved for type 2 diabetes, for cardiovascular risk reduction in adults with type 2 diabetes and established cardiovascular disease, and for kidney outcomes in adults with type 2 diabetes and chronic kidney disease; it has no weight-loss indication [1]. Simvastatin is a statin that lowers LDL cholesterol and reduces cardiovascular events in people at high risk [2].

Two mechanisms could, in theory, connect them. Semaglutide slows gastric emptying and can therefore change how fast an oral drug is absorbed, and simvastatin is a CYP3A4 substrate that is vulnerable to drugs that block that enzyme [1][2]. Neither mechanism produces a listed interaction between these two drugs.

The Ozempic label states that semaglutide delays gastric emptying and has the potential to affect absorption of oral medicines, but that in clinical pharmacology trials it did not affect absorption to any clinically relevant degree, with caution still advised [1]. The label also says Ozempic is not recommended in people with severe gastroparesis [1].

What the absorption studies actually showed

A crossover study in healthy volunteers gave single doses of metformin, warfarin, atorvastatin and digoxin before and during treatment with semaglutide 1 mg at steady state. The exposure ratios for all four stayed within the prespecified 0.80 to 1.25 range, which was the study's definition of no clinically relevant interaction, and there was no clinically relevant change in the warfarin INR response [4]. Atorvastatin is a different statin from simvastatin, and simvastatin itself was not among the drugs tested.

The label for semaglutide tablets reports no clinically significant effect on lisinopril, warfarin, metformin, digoxin, ethinyl estradiol, levonorgestrel, furosemide or rosuvastatin. With those tablets, levothyroxine total exposure rose 33%, and the tablet label advises increased clinical or laboratory monitoring when they are used with oral medicines that have a narrow therapeutic index or that require clinical monitoring [5]. Simvastatin is not among the medicines named.

Simvastatin metabolism and CYP3A4

Simvastatin is a lactone prodrug. After a dose it is hydrolyzed to simvastatin acid, the active HMG-CoA reductase inhibitor. Simvastatin is metabolized by CYP3A4, and simvastatin acid is a substrate of the OATP1B1 transporter [2]. Only a small fraction of an oral dose reaches the general circulation, under 5%, because of extensive first-pass extraction [2].

Semaglutide is broken down by proteolytic cleavage of its peptide backbone and beta-oxidation of its fatty acid side chain rather than by CYP enzymes, and it has very low potential to inhibit or induce CYP enzymes [1]. Simvastatin in turn is not a CYP3A4 inhibitor [2]. Neither drug is listed as changing the other's enzyme handling.

The important simvastatin interaction warnings include strong CYP3A4 inhibitors, cyclosporine, danazol and gemfibrozil [2]. In the label's study, itraconazole 200 mg daily raised the AUC of both simvastatin and simvastatin acid about 13-fold (with simvastatin 80 mg) [2]. Itraconazole, ketoconazole, posaconazole, voriconazole, erythromycin, clarithromycin, nelfinavir, ritonavir, boceprevir, telaprevir, cobicistat-containing products and nefazodone are all listed examples of contraindicated strong CYP3A4 inhibitors, and cyclosporine, danazol and gemfibrozil are contraindicated too [2].

The dose limits that do apply to simvastatin

The Zocor label sets different caps for different interacting drugs. With amlodipine, amiodarone or ranolazine, it says not to exceed 20 mg daily; with verapamil, diltiazem or dronedarone, not to exceed 10 mg daily; with lomitapide, reduce the dose by 50% and do not exceed 20 mg daily [2]. For scale, amlodipine 10 mg daily raised simvastatin acid exposure 1.58-fold, while diltiazem raised it 2.69-fold [2].

Grapefruit juice is a separate warning in the same label, which says to avoid it. In the label's low-intake study, one 8 oz glass of single-strength juice daily for 3 days raised AUC 1.9-fold for simvastatin and 1.3-fold for simvastatin acid. In a 10-volunteer crossover study with very large intake, simvastatin AUC rose 16-fold and simvastatin acid AUC about 7-fold [2][6]. The effect of amounts between these has not been studied [2].

The label's maximum recommended simvastatin dose is 40 mg once daily, taken in the evening. The 80 mg dose is restricted to people who have taken 80 mg chronically (for example 12 months or more) without muscle toxicity, and the label directs anyone who needs a high-intensity statin or misses their LDL goal on 40 mg toward alternative LDL-lowering treatment [2].

Muscle symptoms: the risk that belongs to simvastatin

Simvastatin's myopathy risk is dose-related. In SEARCH, 12,064 survivors of myocardial infarction took 80 mg or 20 mg daily for a mean of 6.7 years: myopathy occurred in 53 people (0.9%) on 80 mg versus 2 people (0.03%) on 20 mg [3]. The label defines myopathy as unexplained muscle weakness, pain or tenderness together with creatine kinase above 10 times the upper limit of normal, and lists age 65 or older, uncontrolled hypothyroidism, renal impairment, interacting drugs and higher doses as risk factors, with risk highest in the first year [2]. It also describes a rare immune-mediated necrotizing myopathy with proximal weakness and persistently high CK after the statin is stopped, and says to discontinue Zocor if that is suspected [2].

On the Ozempic side, the most common adverse reactions reported in 5% or more of patients in placebo-controlled trials were nausea (15.8% on 0.5 mg, 20.3% on 1 mg, 6.1% on placebo), vomiting, diarrhea, abdominal pain and constipation; any gastrointestinal reaction occurred in 32.7% and 36.4% on the two doses versus 15.3% on placebo [1]. In simvastatin's clinical studies of 2,423 adults, constipation was reported in 7% and nausea in 5% [2].

Kidney function and age

The Ozempic label recommends no dose adjustment for renal impairment, and warns about acute kidney injury from volume depletion during nausea, vomiting or diarrhea, especially during dose escalation [1]. The simvastatin label handles kidney function differently: in severe renal impairment (creatinine clearance 15 to 29 mL/min), it says to start at 5 mg daily using another simvastatin product, since Zocor itself is sold only in 10, 20 and 40 mg tablets [2].

Age is also handled differently by the two labels. Being 65 or older is listed as a myopathy risk factor for simvastatin, and mean plasma levels of total inhibitors were about 45% higher in people aged 70 to 78 than in people aged 18 to 30 [2]. Ozempic's glycemic trials found no overall difference in safety or efficacy in patients 65 and older, while noting that greater sensitivity in some older individuals cannot be ruled out [1].